Group items matching

in title, tags, annotations or url

: The Division of Integrative Organismal Systems (IOS) continues to support the Enabling Discovery through GEnomic Tools (EDGE) program, previously a component of the IOS Core Programs solicitation (NSF 16-505). EDGE is designed to provide support for research addressing current impediments to research progress in organismal biology. In particular, the ability to directly test gene function is essential to improve understanding of the genomes-to-phenomes relationship, an area relevant to Understanding the Rules of Life, one of 10 Big Ideas for future NSF investment (www.nsf.gov/about/congress/reports/nsf_big_ideas.pdf). EDGE projects should focus on development of functional genomic tools, approaches, and associated infrastructure to enable direct tests of hypotheses about gene function in diverse organisms for which such tools and infrastructure are presently unavailable. EDGE proposals must include training and rapid dissemination plans enabling larger communities of investigators to utilize the newly-developed tools, thereby catalyzing an increase in the capacity of research communities to test cause-and-effect hypotheses about genes and phenotypes in organisms for which such tools and infrastructure are presently lacking.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.  

GSK is seeking rapid, point of care analytical tests for gene therapy products that can go from sample to result within 2 hours   Tests should work with human cells at a concentration of 1x106 - 1x108 cells per mL in growth media. They should characterize / quantify the populations of cell immunophenotypes in the sample.   Lab tests are welcome. GSK would be especially interested in analytical techniques that could be carried out at or close to the patient's bedside.

Chemical modifications of protein, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests RNA modifications have substantive roles in multiple basic biological processes. Epitranscriptomics can be defined as the aggregate suite of functional biochemical modifications to the transcriptome within a cell. Recent studies in yeast, Drosophila, rodent and human models demonstrate that stressors can induce RNA modifications, with specific reprogramming of some regulatory RNAs. The NIEHS seeks to solicit innovative, mechanistic research applications that are focused on how environmental exposures are associated and involved with the functional activities of RNA modifications and pathways that may be modified or misregulated, associated with adverse health outcomes and/or be useful as biomarkers of exposure and/or exposure-induced pathologies. The study of functional chemical RNA modification has identified important emerging roles in cellular regulation and gene expression. However, the impact of environmental exposures on functional RNA modifications has been relatively understudied and may present a new mechanism for enhanced understanding the relationships between exposures and the development of complex human diseases. The NIEHS will use the R01 mechanism to support hypothesis driven research using approaches that incorporate principles of toxicology with RNA modification biological and/or chemical expertise and utilizes state of the art technologies.

Adeno-associated virus (AAV) vectors, currently considered highly effective, have numerous advantages, such as high expression efficiency, a wide variety of organ-/tissue-specificity, long-lasting expression, and low pathogenicity. However, AAV also has disadvantages: the limitation in size of transgene it can carry; the difficulty in producing it; and that many human adults possess neutralizing antibodies. Therefore, the client has issued this open request to seek a gene delivery technology using non-viral vectors which have greater effect than AAV vectors, or which can overcome the disadvantages of AAV vectors. A technology using a device is also welcome.

This Funding Opportunity Announcement (FOA) encourages investigator-initiated applications that propose hypothesis-driven research using erythroid cells.  The aim of this program is to support research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components function to achieve normal erythropoiesis.  Components include genes that are expressed (transcriptome) in erythroid cells, either during development or during differentiation, chemical changes to DNA and histone proteins (epigenome) and the proteins (proteome) that are translated in erythroid cells, including post-translational modifications or subcellular localizations that are unique to erythroid cells. 

The purpose of this specific FOA is to solicit applications to develop and implement a Knowledge Management Center (KMC) for the Illuminating the Druggable Genome (IDG) Program. The KMC will house, organize, and share metadata and data by accruing and abstracting data and information available in primary literature, databases, and other resources around the world and deploy an integrated informatics solution. However, any proposed human curation efforts will initially focus only on illuminating three major protein families of the IDG project:  non-olfactory G protein-coupled receptors, ion channels and protein kinases. The KMC will identify and scientifically justify the data and resources it proposes to accrue that will enable the biomedical community to easily identify and prioritize protein targets within any gene family to study further. The KMC awardee will be expected to interact and collaborate with all future awardees of the IDG Program, the IDG Consortium, and, future awardees of the IDG CEITs.

Chemical modifications of proteins, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests these RNA modifications (epitranscriptomics) have substantive roles in basic biological processes. Recent studies in yeast, Drosophila and rodent models demonstrate stressors can induce RNA modifications, with specific epitranscriptomic reprogramming of some regulatory RNAs. The purpose of the eFRAMED FOA is to solicit and support R21 applications that propose conducting innovative, high risk, high reward research to enhance our understanding of how environmental exposures impact this layer of cellular regulation.

The PREPARE program aims to develop programmable gene modulators for humans that can provide specific, effective, safe, and transient medical countermeasures and prophylaxes to combat chemical, biological, radiological, and/or nuclear (CBRN) threats.

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). Also Listed under (U44)

The purpose of this Funding Opportunity Announcement (FOA) is to foster research on human long non-coding RNAs (lncRNAs) to understand their roles in controlling the gene regulatory networks underpinning normal Heart, Lung, Blood and Sleep (HLBS) homeostatic and disease processes. 

To that end, grants of up to $5 million will be awarded in support of research on innovative pharmacologic interventions for Alzheimer's disease and related dementias, including clinical trials, regulatory studies for novel drugs (small molecules and biologics, including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.